Approvals & regulatory · first seen 1h ago, updated 1h ago

Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance

1 outlet FDA

SHANGHAI, Sept. 25, 2026 /PRNewswire/ -- Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent…

Summary from PR Newswire - Clinical Trials.

Coverage 1 article · 1 outlet

PR Newswire - Clinical Trials 1h ago
Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance